The departure of senior executives, pharmaceutical companies have been and become the new normal in the pharmaceutical industry.

"Pharmaceutical network industry dynamics" recently, Twa Dongbao issued a notice that the company's board of directors on August 10 received the deputy general manager Han Fengjun submitted a written resignation report - Han Fengjun for personal reasons, the application to resign from the company's deputy general manager.
resignation, Han Fengjun will no longer hold any position in the company.
Executive departures, pharmaceutical companies were, into the new normal pharmaceutical industry in the first half of the drug industry changes frequently originally, pharmaceutical personnel changes are only the industry's normal, but it is worth noting that since this year, according to statistics, the pharmaceutical industry personnel changes frequently, in 2019 revenue of more than 100 million yuan of listed pharmaceutical companies, has more than 69 enterprises have been adjusted.
such as Fosun Pharma, Northeast Pharmaceuticals, Jiuzhitang, Dongcheng Pharmaceuticals, Jiangsu Wu Zhong, Lisheng Pharmaceuticals 6 pharmaceutical executives have left the number of 4 or more people.
, Fosun Pharma's vice president position and Northeast Pharmaceutical's deputy general manager position are in frequent changes.
according to incomplete statistics, in half a year, Fosun Pharma "out" five executives in succession.
changes in personnel in Jiuzhitang were also more frequent, with six executives "out" in the first half of the year.
In January, Yang Lianmin and Gao Jinyan resigned as deputy general manager of Jiuzhitang, and in February, Li Jinsong, Sheng Lockzhu and Liu Guochao resigned from their respective positions as directors of the 7th board of directors and special committees of the board of directors of Jiuzhitang for work reasons and personal reasons.
addition to this, in July alone, 17 pharmaceutical executives, including China National Pharmaceuticals, Hengrui Pharmaceuticals and Gan Li Pharmaceuticals, left their jobs.
, industry insiders said that this year, affected by the outbreak, with volume procurement and other factors, pharmaceutical companies in order to strategic layout to adapt to the policy, the relevant personnel adjustment inevitably change frequently.
In accordance with the relationship between industrial development environment and performance pressure, industry insiders expect that there will be more frequent changes in the future at the top of seven types of enterprises, including single-cost-driven marketing enterprises, capital-based mergers and acquisitions of consolidation enterprises, public relations-based opportunity-based enterprises, based on research and development advantages of long-term windfall pricing enterprises, based on simple profit distribution of investment enterprises, enterprises in the field of rapid concentration of professional areas, and excessive superstition tactics ignore strategic research enterprises.
, in addition to frequent personnel adjustment, mergers and acquisitions between pharmaceutical companies have also accelerated this year.
August 5, People's Fu Pharmaceutical Group Co., Ltd. announced that it intends to transfer its 70% stake in Sichuan People's Fu Pharmaceutical Co., Ltd. to Chongqing Pharmaceutical (Group) Co., Ltd. for 362 million yuan.
July 24th, The State Pharmaceuticals announced that it had successfully delisted the company into a 100% equity transfer project with a transaction price of 1.86 billion yuan.
same day, the National University pharmacy and Liaoning Cheng university signed the "property rights transaction contract."
July 23, Step Pharma announced that it will transfer a 51% stake in its controlling subsidiary, Hubei Step Kyusyus public pharmaceutical Co., Ltd., to Kyusyusyusyus pharmaceutical group co., Ltd. at a price of RMB21,752,298.32.
July 6, Hubei Provincial Drug Administration issued a notice that Huafeng Pharmaceutical Co., Ltd. in Feng County to carry out mergers and reorganization, the new declaration issued Hubei Xuanming Pharmaceutical Technology Co., Ltd. "drug business license."
Taken together, since 2020, with China's medical reform into the deep water area, especially with the volume of procurement, consistency evaluation, and medical reform anti-corruption and upgrading pressure, generic drug prices dived into the era of micro-profit, and innovative drugs become a new breakthrough direction of the background, the entire industry is facing the urgent need for transformation and upgrading.
also means that volatility in China's pharmaceutical industry, including personnel changes, mergers and acquisitions, will continue over the next few years.
.